ACE2 and migraine disorder: Ace2 has been described to be associated with increased risk of nonspecific orofacial symptoms in the OPPERA (Smith et al., 2013) prospective study, and Ace is linked to migraine and potentially higher frequency as well as susceptibility (Dandona et al., 2007).